Hikma Sues Eagle Over $3.5M Generic-Drug Rights Deal

Law360, New York (June 25, 2013, 4:29 PM EDT) -- Hikma Pharmaceuticals LLC sued Eagle Pharmaceuticals Inc. in New York federal court Monday, alleging Eagle had failed to win timely regulatory approval as required under a $3.5 million generic-drug rights transfer deal due to manufacturing problems it fraudulently concealed, then refused to refund the money.

According to the Jordanian drugmaker, Woodcliff Lake, N.J.-based Eagle had hidden problems in the development of the unspecified generic drug prior to Hikma agreeing to acquire the rights to the drug, then wrongly refused to refund the money paid under the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.